Re-Evaluating Growth Opportunities In Vascular Interventional Device Markets
Manufacturers are finding it harder to innovate in the vascular interventional device arena as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in the areas of renal denervation, drug-coated balloons, and renal artery stenting; still there are areas of opportunity that continue to look promising, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.
You may also be interested in...
Two very different ways to treat peripheral arterial disease – lithotripsy combined with angioplasty and nitinol Tack implants – have demonstrated impressive six-month and one-year clinical results, respectively, and companies with these devices continue to attract funding.
The market for peripheral vascular interventions and diagnostics is poised for significant growth in the years ahead, driven by an aging population and the growing incidence of peripheral vascular disease, along with new technological developments such as drug-eluting balloons, which are inching closer to regulatory approval in the US.
The market opportunity for TAVR is significant, with 2013 sales totaling $303.4 million in the US and $765 million outside the US, and those numbers are expected to grow to an estimated $1.29 billion and $1.63 billion, respectively, by 2018. Edwards and Medtronic dominate the worldwide market at present, but other companies are expected to make inroads with next-generation devices designed to optimize outcomes.